The Filing Desk

Alumis vs Aquestive Therapeutics

Alumis ALMS · Aquestive Therapeutics AQST · Pharmaceuticals

Aquestive Therapeutics reported revenue of $44 million in fiscal 2025, 1.9 times Alumis' $24 million in fiscal 2025. Alumis had an operating margin of -1886.9%, against -159.5% at Aquestive Therapeutics. Free cash flow was −$370 million at Alumis and −$53 million at Aquestive Therapeutics.

Side by side

AlumisAquestive Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$24M$44M
Revenue growth—−22.6%
Revenue growth a year, last 5 years—−0.6%
Gross margin—58.4%
Operating margin−1,886.9%−159.5%
Net margin−1,011.8%−188.1%
Free cash flow−$370M−$53M
Free cash flow margin−1,539.2%−119.0%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count200.0%23.3%
Last close$5.60$3.91
P/E at the last close——
Insider trades, last 12 months——
Piotroski F-score—2 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
AlumisAquestive Therapeutics
Operating margin
Percent of revenue
AlumisAquestive Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AlumisAquestive Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Alumis and Aquestive Therapeutics pages.